Coherus BioSciences, Inc. (CHRS)

NASDAQ: CHRS · IEX Real-Time Price · USD
2.500
-0.080 (-3.10%)
At close: Feb 26, 2024, 4:00 PM
2.512
+0.012 (0.48%)
Pre-market: Feb 27, 2024, 8:00 AM EST
-3.10%
Market Cap 272.28M
Revenue (ttm) 211.07M
Net Income (ttm) -217.11M
Shares Out 111.36M
EPS (ttm) -2.62
PE Ratio n/a
Forward PE 32.89
Dividend n/a
Ex-Dividend Date n/a
Volume 6,987
Open 2.560
Previous Close 2.580
Day's Range 2.430 - 2.650
52-Week Range 1.430 - 8.650
Beta 0.53
Analysts Strong Buy
Price Target 9.60 (+284.0%)
Earnings Date Mar 12, 2024

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the Un... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2014
Employees 299
Stock Exchange NASDAQ
Ticker Symbol CHRS
Full Company Profile

Financial Performance

In 2022, CHRS's revenue was $211.04 million, a decrease of -35.37% compared to the previous year's $326.55 million. Losses were -$291.75 million, 1.62% more than in 2021.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price forecast is $9.6, which is an increase of 284.00% from the latest price.

Price Target
$9.6
(284.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committ...

3 days ago - GlobeNewsWire

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDE...

5 days ago - GlobeNewsWire

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduce...

22 days ago - GlobeNewsWire

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

– Transaction aligns to Coherus' strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –

5 weeks ago - GlobeNewsWire

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –

5 weeks ago - GlobeNewsWire

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

-  Combination therapy to be evaluated in a Phase 3  trial in patients with locoregionally advanced ,  high-risk ,  HPV16/18 - positive head and neck cancer PLYMOUTH MEETING, Pa. and REDWOOD CITY, Cal...

Other symbols: INO
7 weeks ago - PRNewsWire

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan...

7 weeks ago - GlobeNewsWire

Coherus Announces U.S. Launch of LOQTORZI™

– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1 st  line treatment and as monotherapy for patient...

7 weeks ago - GlobeNewsWire

2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.

The S&P 500 index SPX has three days left this year to try for a fresh record high, which in theory, shouldn't be so hard with a Santa Rally all but teed up.

2 months ago - Market Watch

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgr...

2 months ago - GlobeNewsWire

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemothe...

2 months ago - GlobeNewsWire

Coherus BioSciences Announces CFO Transition Plans

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the c...

2 months ago - GlobeNewsWire

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses –

2 months ago - GlobeNewsWire

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

– Net revenue rose 27% from prior quarter to $74.6 million – – CIMERLI® net sales increased 50% to $40 million compared to prior quarter – – LOQTORZI™ now approved with launch planned for the first qu...

4 months ago - GlobeNewsWire

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –

4 months ago - GlobeNewsWire

Coherus BioSciences to Participate at Upcoming November Investor Conferences

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conference...

4 months ago - GlobeNewsWire

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market ...

4 months ago - GlobeNewsWire

Intuitive Machines stock climbs on lunar mission plan as McDonald's edges higher ahead of results

Coherus BioSciences stock CHRS, -3.65% rose 17% as the Food and Drug Administration approved its treatment for nasopharyngeal cancer when combined with chemotherapy that it makes with Shanghai Junshi ...

Other symbols: MCD
4 months ago - Market Watch

Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemoth...

4 months ago - GlobeNewsWire

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

– Resubmission follows the satisfactory resolution of the FDA's review of inspection findings at  the third-party filler –

5 months ago - GlobeNewsWire

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* – – Demonstrated safety and efficacy in clinical trials and real-world settings – – Robust and reliable supply addresses ...

5 months ago - GlobeNewsWire

Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day

- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments -

5 months ago - GlobeNewsWire

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipe...

5 months ago - GlobeNewsWire

Coherus BioSciences' new injector treatment for cancer patients rejected by FDA

Coherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udenyca, a treatment designed to cut cancer patients' r...

5 months ago - Market Watch

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections

– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL –

5 months ago - GlobeNewsWire